BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $20.70 Consensus Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $20.70.

Several research firms recently commented on BCRX. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC reduced their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Citizens Jmp raised their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Royal Bank Of Canada reduced their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Finally, Wedbush reduced their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the transaction, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC grew its holdings in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares in the last quarter. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals during the 3rd quarter worth about $77,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares in the last quarter. Hilltop Holdings Inc. bought a new position in BioCryst Pharmaceuticals during the 1st quarter worth about $98,000. Finally, Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals during the 4th quarter worth about $81,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $9.02 on Wednesday. The company has a market capitalization of $2.29 billion, a PE ratio of -5.07 and a beta of 0.57. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31. The firm’s 50-day moving average is $9.16 and its 200 day moving average is $7.91.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The company had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.20 EPS. Sell-side analysts forecast that BioCryst Pharmaceuticals will post 0.31 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.